Ass. Prof. Fotios Loupakis, Prof. Hans Prenen and Ass. Prof. Joleen Hubbard discuss the Clinical Question: How to treat (or not) elderly colorectal cancer patients? Unfit: a relative concept

Hans Prenen obtained his medical degree and PhD at the Catholic University Leuven. He is currently the head of the Medical Oncology Department at the University Hospital Antwerp and director of the Oncology Clinical Trial Unit. He is member of several scientific organisations including the Belgian Society of Medical Oncology (board member since 2015) and the European Society of Medical oncology (scientific committee). He is a recognised international expert in the field of cancer and is regularly invited to national and international meetings and has published more than 200 peer reviewed scientific papers. He is principal investigator of several clinical trials with a focus on phase 1 and basket trials. His research interests relate to translational studies on targeted therapies, new anticancer therapies and understanding the molecular changes induced by anticancer therapy.

Dr Joleen Hubbard is Deputy Director of Clinical Research and Academic Affairs for the Allina Health Cancer Institute in Minneapolis, Minnesota.  She was previously Assistant Professor of Medical Oncology at Mayo Clinic. She completed medical school and residency at the University of Minnesota and haematology/oncology training at Mayo Clinic, Rochester, Minnesota. Dr Hubbard specialises in the treatment of gastrointestinal cancers, focusing on colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials, investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology with a special interest in clinical and biologic markers of frailty. She serves as a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. 

Assoc. Prof. Joleen Hubbard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory boards: Bayer, Merck, BeiGene, Incyte

Research funding to institution: Merck, Boston Biomedical, Treos Bio, Senhwa Pharmaceuticals, Bayer, Incyte, TriOncology, Seattle Genetics, Hutchison MediPharma, Pionyr Immunotherapeutics, Trovogene, G1 Therapeutics, Roche

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast
Oncology 
HR+/HER2- metastatic breast cancer: Best practices in molecular testing and targeted therapy

Optimising precision medicine for improved patient outcomes

Experts
Dr Roberto Salgado, Assoc. Clinical Professor Rena Callahan
Endorsed by
ICAN international cancer advocacy network ISLB Exon20group
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
conference-update Conference update
Oncology 
Current and future treatment strategies for patients with ER+/HER2- early breast cancer

A closer look at the evolving treatment landscape

Experts
Prof. Michael Gnant, Prof. Giuseppe Curigliano
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Mar 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Oncology 
ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses

Experts' insights on treatment strategies in ER+ metastatic breast cancer settings

Experts
Dr Aditya Bardia, Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
LEAP-012 publication snapshot

Expert insights on multimodal treatment for intermediate hepatocellular carcinoma (HCC)

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery plus
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
eks
Experts Knowledge Share Video
Oncology 
HER2 testing: The evolving role of immunohistochemistry (IHC)

Best practices and interpretation of results in lung and ovarian cancer 

Experts
Prof. Fernando López-Ríos, MD, PhD, Prof. Christian Rolfo, Prof. Charlie Gourley
Endorsed by
Exon20group ICAN international cancer advocacy network Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 77 MIN
  • calendar Mar 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
conference-update Conference update
Oncology 
ER+ metastatic breast cancer: Highlights from the 13th APBCS Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer  

Experts
Prof. Shaheenah Dawood, Prof. Heather McArthur, Prof. Javier Cortés, Prof. Frédérique Penault-Llorca
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.